24 Apr 2018 07:00
For immediate release | 24 April 2018 |
|
|
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Presentation at World Orphan Drug Congress USA
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that Steve Franklin, the Company's CEO, will present at the World Orphan Drug Congress USA 2018 in Maryland, Washington DC, on 26 April 2018.
The presentation, which is part of the Pitch & Partner track of the congress, will focus on SFX-01, the Company's lead product, in the treatment of subarachnoid haemorrhage ("SAH"). SFX-01 is currently in a Phase II clinical trial in SAH, which remains on track to report around the end of 2018.
The presentation will also refer to the ongoing Phase II trial of SFX-01 in metastatic breast cancer, which is on track to report an interim read-out in Q2 this year with the final read-out around the year end.
The World Orphan Drug Congress USA 2018, which will take place on 25-27 April 2018, focuses on all aspects of orphan drug development and rare disease research. Further details are available at the congress website: http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.
This will be the second international forum that Steve Franklin has been invited to address this month, having just returned from a closed meeting in Madrid where he presented the "SFX-01 for Subarachnoid Haemorrhage" clinical programme to senior scientists from pharmaceutical companies and academia, all with a common interest in the Nrf-2 pathway.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com | c/o +44 (0) 20 7466 5000
| |
|
| |
Buchanan Mark Court, Sophie Wills, Stephanie Watson | +44 (0) 20 7466 5000
| |
|
| |
Northland Capital Partners Limited Matthew Johnson, Tom Price, Gerry Beaney (Corporate Finance) John Howes, Rob Rees (Corporate Broking) | +44 (0) 20 3861 6625 | |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/